PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pomalidomide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

22 hits

Bibliografisk träff 2013-07-01

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C.

Immunology · research support, non-u.s. gov't; journal article · DOI 10.1111/imm.12087

Bibliografisk träff 2013-04-01

A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.

Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA.

J Thorac Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1097/jto.0b013e318282707b

Bibliografisk träff 2013-02-01

Immunomodulatory drugs in multiple myeloma.

Andhavarapu S, Roy V.

Expert Rev Hematol · review; journal article · DOI 10.1586/ehm.12.62

Bibliografisk träff 2013-01-14

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T, Intergroupe Francophone du Myélome.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1182/blood-2012-09-452375

Bibliografisk träff 2012-12-25

Novel immunomodulatory compounds in multiple myeloma.

Saini N, Mahindra A.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2013.749235

Bibliografisk träff 2012-12-14

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.

Blood · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2012-08-450742

Bibliografisk träff 2012-12-01

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G.

Cancer Chemother Pharmacol · clinical trial; research-article; journal article · DOI 10.1007/s00280-012-2040-6

Bibliografisk träff 2012-11-23

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exphem.2012.11.005

Bibliografisk träff 2012-09-28

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.

Zhu YX, Kortuem KM, Stewart AK.

Leuk Lymphoma · research-article; review; journal article · DOI 10.3109/10428194.2012.728597

Bibliografisk träff 2012-09-11

Thalidomide and its analogues in the treatment of Multiple Myeloma.

Latif T, Chauhan N, Khan R, Moran A, Usmani SZ.

Exp Hematol Oncol · review-article; journal article · DOI 10.1186/2162-3619-1-27

Bibliografisk träff 2012-08-17

Pomalidomide is effective for prevention and treatment of experimental skin fibrosis.

Weingärtner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, Beyer C, Shankar SL, Cedzik D, Schafer PH, Distler O, Schett G, Distler JH.

Ann Rheum Dis · research support, non-u.s. gov't; journal article · DOI 10.1136/annrheumdis-2012-201784

Bibliografisk träff 2012-08-09

Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1919-6

Bibliografisk träff 2012-06-20

Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.

De Keersmaecker B, Allard SD, Lacor P, Schots R, Thielemans K, Aerts JL.

J Virol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/jvi.00472-12

Bibliografisk träff 2012-06-06

Immunomodulatory agents in myelofibrosis.

Tabarroki A, Tiu RV.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.693913

Bibliografisk träff 2012-05-14

Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?

Linhares YP, Pavletic S, Gale RP.

Bone Marrow Transplant · research support, non-u.s. gov't; review; journal article; research support, n.i.h., extramural · DOI 10.1038/bmt.2012.76

Bibliografisk träff 2012-05-03

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R.

Leukemia · research-article; journal article · DOI 10.1038/leu.2012.119

Bibliografisk träff 2012-04-04

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.

Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2012-02-413161

Bibliografisk träff 2012-04-01

Breakthroughs in myeloproliferative neoplasms.

Santos FP, Verstovsek S.

Hematology · review; journal article · DOI 10.1179/102453312x13336169155574

Bibliografisk träff 2012-04-01

Novel therapeutics in multiple myeloma.

Stewart AK.

Hematology · research-article; journal article · DOI 10.1179/102453312x13336169156131

Bibliografisk träff 2012-04-01

Targeted therapy of multiple myeloma.

Kyle RA.

Hematology · journal article · DOI 10.1179/102453312x13336169156339

Bibliografisk träff 2012-03-01

Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Barosi G, Lupo L, Rosti V.

Curr Hematol Malig Rep · review; journal article · DOI 10.1007/s11899-011-0109-7

Bibliografisk träff 2011-11-12

Long-term outcome of pomalidomide therapy in myelofibrosis.

Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A.

Am J Hematol · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1002/ajh.22233